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Abstract
Background: Soy-derived isoflavones potentially protect against obesity and depression. In five different studies
we examined the influence of soy-containing diets or equol injections on depression, serotonin levels, body weight
gain (BW) and white adipose tissue (WAT) deposition in female Long-Evans rats at various stages of life [rats were
intact, ovariectomized or experienced natural ovarian failure (NOF)].
Results: In general, animals fed a soy-rich diet (Phyto-600) and/or administered equol (@ 5 mg/kg/day) displayed
significant decreases in BW and WAT compared to a low-soy diet. When equol was injected alone (5 mg/kg/day),
experiments 1, 4, and 5 demonstrated that body weight was significantly decreased. Equol has body weight
control effects in females that are dependent on ovarian status and/or age of diet initiation. Experiments 1-4 all
displayed no significant differences in depressive-related behavior as measured by the Prosolt forced swim test
(PFST) when soy-rich (Phyto-600) or low-soy diets (Phyto-low) or equol treatments (5 mg/kg/day) were tested in
female rats at various ages or hormonal status. Results of all the experiments are not presented here due to space
limitations, but data from experiment 5 are presented. From conception female rats were exposed to either: a) a
soy-rich (Phyto-600) or b) low-soy diet (Phyto-low). After 290 days all rats experienced NOF. At 330 days-old the
animals were examined in the Porsolt forced swim test (PFST). One month later a second PFST was performed
[after Phyto-low fed animals were injected with equol (5 mg/kg/day) for one week prior to the second PFST]. At
the first PFST, serotonin and mobility levels were significantly decreased in the Phyto-low fed animals compared to
animals that consumed the Phyto-600 diet. After equol injections at the second PFST, mobility and serotonin levels
significantly increased in aged NOF rats fed the Phyto-low diet (to levels comparable to Phyto-600 fed animals).
Conclusions: Consumption of dietary isoflavones or equol exposure in rats has body weight controlling effects
and equol specifically may have antidepressant potential dependent upon diet initiation and/or dosage of
treatments. The current study demonstrates that equol is able to decrease body weight, abdominal WAT, and
depressive-related behavior. While other factors and mechanisms may play a role, in part, the present results
provide a greater understanding of how isoflavonoid molecules modulate the brain’s influence on behavior.
Background
Following the 2002 Women’s Health Initiative (WHI),
concerns about hormone replacement therapy (HRT)
amplified interest in alternative therapies for the treat-
ment of menopausal symptoms [1-3]. Polyphenols are
plant-derived substances that are available as dietary sup-
plements [4,5]. The best-studied are the phytoestrogens,
which include isoflavones, lignans, and coumestans [5-7].
Of these, isoflavones are the type most commonly found
in both rodent and human diets [8] and have shown
potential as treatments for a number of age-related disor-
ders, such as, cardiovascular disease, breast and prostate
cancers [9].
Isoflavones, such as daidzein and genistein, are selec-
tive estrogen receptor modulators (SERM) or biochem-
ical compounds that are able to agonize or antagonize
estrogen receptors (ER) [10]. Daidzein and genistein are
able to bind both ERa and ERb but demonstrate a higher
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any medium, provided the original work is properly cited.affinity for ERb [8,10]. Moreover, daidzein’s intestinally
produced metabolite, equol, has a higher affinity for ERb
than daidzein or genistein [11]. This chemical character-
istic of equol to bind estrogen receptor subtypes indicates
potential as an alternative treatment to HRT for meno-
pausal symptoms.
Menopausal symptoms such as hot flashes, insomnia,
depression, and weight gain are associated with the loss
of ovarian steroid production and availability [1,12-14].
HRT effectively decreases these symptoms and is the
only current treatment approved by the FDA [1]. How-
ever, since the 2002 WHI raised the concern that HRT
increases cancer risk, researchers, health professionals,
and postmenopausal women are looking for other ways
to treat menopausal symptoms [1,3]. Due to the varying
actions and distributions of ERa and ERb, specific treat-
ments can now be administered that target either recep-
tor [15,16]. For example, isoflavonoids via ERb,d u et o
this estrogen subtype’s distribution and interactions with
other molecules and receptors, potentially may play an
important role as an HRT alternative [7,15,16].
In a series of reports we demonstrated that soy-
derived isoflavones can significantly decreased body
weight, adipose tissue deposition, skin tail temperature
and produce anxiolytic effects [17-20]. Notably, in a
comprehensive study the beneficial influences of soy-
derived isoflavones via diet were examined that included
body weight, adipose tissue deposition, food and water
intake, metabolic hormones (i.e. leptin, insulin, thyroid
(T3) and glucose levels), brain neuropeptide Y (NPY)
levels in hypothalamic regions, heat production [in
brown adipose tissue (BAT) quantifying uncoupling pro-
tein (UCP-1) mRNA levels] and core body temperature
[19].
Thus, this stimulated us to examine whether isofla-
vones (particularly equol) may be used as both an anti-
depressant and an anti-obesity treatment in intact
female rats and two animal models of menopause (ovar-
iectomy and natural ovarian failure).
Methods
General methodology
In five different experiments we examined the influence
of soy-containing diets and equol administered via sub-
cutaneous (s.c.) injections on depressive-like behaviors,
serum serotonin levels, weight gain (BW) and white adi-
pose tissue (WAT) deposition in female Long-Evans rats
at various stages of postnatal life.
Animals, mating and housing
All animals had free access to food (diet treatment)
and tap water. Only the animals in Experiment 3 were
not bred at our facilities. [The Experiment 3 rats were
purchased ovariectomized (at approximately 45-50
days-old) from Charles River Laboratories (CRL) and
following surgery/recovery the animals were shipped
to our facilities.] All other male and female rats pur-
chased from the supplier (CRL, at approximately
50-55 days-old) were allowed time to adapt to their
new surroundings and diet treatments before being
bred in our animal facilities at approximately 90 days
old for each experiment (outlined below). Mating was
performed by a protocol previous reported by our
laboratory [18]. In brief, all of the males were fertile
and each male inseminated 2 to 4 females by diet
treatment by experiment. After birth the pups
remained on the same diets as their mothers. At age
21 days the rats were weaned and housed in cages
[standard shoebox (20 cm high × 24 cm wide × 40 cm
deep) containing wood/shaving-chip bedding] with
3 to 4 animals per cage by treatment. At 40 days of
age the animals were separated (2 animals per cage by
treatment) until 60 days of age when 1 animal per
cage defined the housing protocol until the end of all
the experiments.
Diets
From conception (except for Experiment 3 where ani-
mals were ovariectomized at that supplier, see above;
i.e., the diet for these animals from conception until
arrival at our facilities was a Phyto-200 diet, see results
section) the female rats were exposed to either a soy-
r i c h( P h y t o - 6 0 0 )d i e tt h a tc ontained 600 ppm of isofla-
vones (Harlan Teklad 8604, Madison, WI, USA) or a
low-soy (Phyto-low) diet that contained approximately
10 ppm of isoflavones (Zeigler Bros. Inc., Gardners, PA,
USA), (catalog # 541200-12-00, Rodent PHY RDC).
Each diet protocol is outlined below by experiment
number and descriptor. Furthermore, the diet formula-
tions (ingredient list) have been published previously
[17-19]. Notably, for the soy-rich (Phyto-600) diet, soy
meal is the first ingredient and this diet treatment does
not contain a soy protein isolate. This was accomplished
by placing the males and females that were bred at our
animal facilities on the respective diets by each experi-
mental design (as outlined above).
Injections
In general, before running the last Porsolt Forced Swim
Tests rats received subcutaneous (s.c.) injections (@
nape of the neck) of either dimethyl sulfoxide @ 100%
(DMSO, HPLC grade; Sigma Chemical Co., St. Louis,
MO, USA) that served as controls or 5.0 mg/kg body
weight of equol (Central Glass Co., Kuensebeck,
Germany) in DMSO. Daily injection volume was 0.1 cc
(see specific experiment number below for injection sche-
dule). While the length of time injected differed between
experiments the equol concentration remained at 5 mg/kg
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equol dose of 2.5 mg/kg yielded similar results].
Ovariectomy
Animals in Experiment 4 were ovariectomized in our
laboratory between 96-100 days of age. Animals were
anesthetized with a combination of (3 cc buprenex, 2 cc
domitor and 5 cc of ketamine) at 0.05 cc per 100 grams
body weight. Body temperature was maintained with a
warm water blanket. Both ovaries were surgically
removed (with the assistance and supervision of our
university veterinarian), the incision was closed with
sterile surgical staples and animals were given acetami-
nophen [20 ml of pediatric elixir (32 mg/ml) per 500 ml
tap water] in their drinking water for approximately
4-5 days post-surgery during recovery.
Porsolt forced swim test
We utilized the Porsolt forced swim test (PFST) that has
become a standard antidepressant test in pharmaceutical
laboratories worldwide and in academic laboratories for
investigating the neurobiology of depression and of anti-
depressant agent action [21,22]. It tests depressive-like
behaviors by quantifying an animal’s mobility and
immobility and associated behaviors.
Each rat was placed in a plastic cylindrical container
(diameter, 19 cm, height, 43 cm) containing water at a
d e p t ho f3 5 . 6c mf o r8m i n u t e s .R a t sw e r eu n a b l et o
touch the bottom of the container with their tails [23].
The behavior was then recorded both by a video camera
above and experienced observers to the side. Swimming
speed, distance, time spent both mobile and immobile
were recorded. Animals that express fewer depressive-
related behaviors spend more time mobile, swim farther
and have a higher overall average swimming speed. Ani-
mals that express depressive-related behaviors, spend
more time immobile, swim for a shorter distance, and
have an overall slower average swim speed. All beha-
viors were analyzed by Anymaze
® computer software
(Stoelting Co., Wood Dale, IL, USA).
Body weight, white adipose tissue (WAT) deposition and
blood collection
Body weight (in grams) was recorded at different inter-
vals for each experiment (see below). At the end of each
experiment, trunk blood was collected, serum prepared
a n dt h e ns t o r e da t- 2 0 ° Cu n t i la s s a y e df o rs e r o t o n i no r
isoflavone concentrations. WAT was dissected from just
below the diaphragm to the base of the pelvic cavity and
recorded in grams.
Serotonin ELISA
Serum serotonin levels were quantified using ELISA kits
(Cat# IB89527-121610) purchased from Immuno
Biological Laboratories (Minneapolis, MN, USA). Serum
was analyzed for all of the experiments except experi-
ment 3.
Serum phytoestrogen levels
Serum was analyzed via gas chromatography/mass spec-
trometry (GC/MS) and the circulating isoflavones: genis-
tein, daidzein, and equol concentrations were determined
(ng/ml) using internal control standards, as previously
reported in other studies by our laboratory [18,19].
IACUC approval
All methods associated with animal use/surgery were
approved by the Institutional Animal Care and Use
Committee at Brigham Young University.
Treatments
Experiment 1: Phyto-low diet exposure from concep-
tion to 120 days post-birth with diet change of one-
half of the animals to a Phyto-600 diet until 210 days
of age This experiment examined the influence of diet
on body weight, WAT, serotonin levels, isoflavone
levels, and behavior as measured in the PFST. From
conception to young adulthood, 23 female rats repre-
senting 6 litters were fed the Phyto-low diet. At age
120 days animals were run on the Porsolt forced swim
test (PFST) to obtain baseline levels for depressive-like
behaviors in Phyto-low fed female rats. Following this
PFST, 12 animals were switched to a Phyto-600 diet while
11 animals remained on the original Phyto-low diet. The
animals remained on these diet treatments (Phyto-600 or
Phyto-low) until the end of this experiment. When ani-
mals were age 155 days they were run a second time on
the PFST and behavioral parameters were recorded. From
age 194 to 200 days, the Phyto-low fed animals received
5 mg/kg (body weight) injections of equol while the
Phyto-600 animals received vehicle-DMSO injections. At
age 200 days the animals were run on a third PFST and
behavioral parameters were recorded. The dietary and
treatment injections continued until the animals were
sacrificed at age 210 days when body and WAT weights
were recorded and blood was collected for serotonin and
isoflavone quantification (Figure 1).
Experiment 2: Phyto-low or Phyto-600 diet exposure
by treatment group from conception to 145 days of age
This experiment examined the influence of a low soy-
containing diet (Phyto-low) or a soy-rich (Phyto-600)
diet from conception to adulthood (145 days-old) in
intact rats for the study parameters. Animals were fed
either the Phyto-low (n = 8, representing 4 litters) or
the Phyto-600 (n = 7, representing 3 litters) diet. Ani-
mals were weighed three times a week. When the rats
were 115 days-old the rats were run on the first PFST.
After 3 weeks the Phyto-low fed animals were injected
for 4 days (136 to 142 days-old) prior to second PFST
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received vehicle-DMSO injections. At 142 days-old the
animals were run on a second PFST. These injections
continued until the animals were sacrificed at 145 days-
old when body and WAT weights were recorded and
trunk blood was collected for quantification of serotonin
and isoflavones concentrations (Figure 1). [Note: the
animals in experiment 2 were culled (due to the large
number of litters) which excluded the lightest and heavi-
est animals by diet treatment before 145 days of age].
Experiment 3: Phyto-200 (200 ppm of isoflavones)
diet exposure from conception to 45 days post-birth
at the supplier (ovariectomized). Upon arrival (45
days of age) all animals were changed to the Phyto-
low, then one-half of the animals where changed to a
P h y t o - 6 0 0d i e ta t8 5d a y so fa g eu n t i l1 0 0d a y so l d
This experiment examined initially the influence of a
low soy-containing diet (Phyto-low) diet from approxi-
mately 50-55 days of age until 80-85 days of age in
twenty-two ovariectomized rats purchased from Charles
River Laboratories. The animals were weighed daily dur-
ing this experiment. At approximately age 85 days ele-
ven animals were changed to a soy-rich (Phyto-600) diet
while the other eleven animals remained on the original
soy-low or Phyto-low diet for approximately two weeks.
When the animals were approximately age 100 days
they were tested in the PFST. The animals were then
sacrificed and body and WAT weights were recorded
and blood collected for subsequent analysis of isoflavone
concentrations (Figure 1).
Experiment 4: Phyto-low or Phyto-600 diet exposure
from conception to approximately 100 day old when
all animals were ovariectomized. Then the animals
remained on their respective diet treatments (Phyto-
low or Phyto-600) until 222 days of age This experi-
ment examined the influence of either a low soy-
containing diet (Phyto-low) or a soy-rich (Phyto-600)
diet from conception to adulthood (222 days-old) on the
study parameters. Animals were initially intact rats and
later ovariectomized (in our laboratory) as young adults.
The females were fed either the Phyto-low (n = 8 from
4 litters) or Phyto-600 (n = 8 from 3 litters) diet.
Animals were weighed three times a week. Animals
were ovariectomized at approximately age 100 days. At
age 150 days animals were run on the PFST and beha-
vioral parameters were recorded. The animals continued
on their respective diet treatments until age 200 days
when they were run on a second PFST. However, four
days prior to this second PFST (from age 197 to age
200 days) the Phyto-low fed animals received s.c. injec-
tions of 5 mg/kg of equol and the Phyto-600 fed animals
were administered vehicle-DMSO injections. After the
second PFST animals continued to received daily s.c.
injections by dietary treatments until being run on a
Figure 1 Experiments Summary Figure. D.S. = diet-switched; PFST = Porsolt forced swim test; T.C. = tissue collection; OVX = ovariectomy; NOF =
natural ovarian failure; Red bar = Phyto-low diet; Green bar = Phyto-600 diet; Black bar = supplier diet; Green box = equol injections; orange
diamond = white adipose tissue significantly less; blue square = body weight significantly less; down purple triangle = time immobile significantly
lower, D.O. = days old; ~ = approximately.
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ments continued until animals were sacrificed at age
222 days when the study parameters were collected
(body/WAT weights) and quantified (serum serotonin
and isoflavone levels) (Figure 1).
Experiment 5: Phyto-low or Phyto-600 diet exposure
from conception to until the end of the experiment at
365 days of age. All females experienced NOF at
around 295 days old This experiment examined the
influence of a low soy-containing diet (Phyto-low; n =
6) or a soy-rich (Phyto-600; n = 8) diet from conception
to mid-age on the study parameters in intact rats
(representing at least 2 to 3 litters by dietary treatment)
that experienced natural ovarian failure (NOF). Intact,
Long-Evans female rats were exposed to a Phyto-low
diet or a Phyto-600 lifelong from conception to mid-age
(> 300 days-old). The animals were weighed at selected
time intervals in this experiment. At approximately 300
days-old all animals (regardless of diet treatment)
experienced NOF as detected by vaginal histological/
microscopic examination of the epithelial cells over a
10-day interval (from 295 to 305 days-old). Twenty-
seven days later approximately one half of the animals
in each treatment group had blood collected via tail
vein for baseline serotonin and isoflavone levels. At 330
days-old the animals (by dietary treatment group) were
run on the first PFST. Twenty-four days later (@
approximately 353 days-old) the Phyto-low fed animals
received daily s.c. injections of equol (@ 5 mg/kg) while
the Phyto-600 fed animals received vehicle-DMSO
injections for 7 consecutive days. Two hours after the
last injection on the seventh day the animals were again
run for a second time on the PFST (by diet and injec-
tion treatments). Injections continued until animals
were sacrificed at 365 days-old; body and WAT weights
were recorded and trunk blood was collected for quan-
tification of serotonin and isoflavones concentrations
(Figure 1).
Statistical analysis
Two-sample student t-tests with repeated measures
were used to compare each of the parameters examined
between the two treatment groups in each experiment
or non-parametric analysis with repeated measures,
where appropriate. All statistics were run using the
Minitab statistical software, p < 0.05 was considered
significant. All results are presented as MEANS ± SEM
in all of the graphs and significant differences are
marked.
Results
Results from the overall study are displayed in Figure 1
with each experiment’s major points of significance and
corresponding age highlighted.
Experiments 1, 2, 3 and 4
Body weight and WAT: Body weight changes and white
adipose tissue deposition levels over each treatment period
for experiments 1, 2, 3 and 4 are displayed in Figures 2, 3,
4, 5
In each experiment, prior to each PFST or tissue collec-
tion, body weights were analyzed and the corresponding
values (for BW, WAT, and WAT/BW) and significance
are shown in Table 1.
In general, the animals fed the Phyto-600 diet dis-
played lower body weight gain. However, statistically
significant differences were only seen following the diet
change in experiment 1 and following ovariectomy in
experiment 4.
In experiment 1: Phyto-low diet exposure from con-
ception to 120 days post-birth with diet change of one-
half of the animals to a Phyto-600 diet until 210 days of
age.
The Phyto-600 animals displayed significantly decreased
weight gain following the change to the Phyto-600 diet
(Figure 2). Within 6 days these animals weighed signifi-
cantly less than the Phyto-low animals (p < 0.031) which
continued to the end of the experiment. WAT values were
also significantly lower in the Phyto-600 animals (p <
0.003).
In experiment 4: Phyto-low or Phyto-600 diet expo-
sure from conception to approximately 100 day old
when all animals were ovariectomized. Then the animals
remained on their respective diet treatments (Phyto-low
or Phyto-600) until 222 days of age.
The Phyto-600 females had significantly lower body
weights following ovariectomy (p < 0.01; Figure 5). This
difference continued until animals were 212 days-old at
which point these there was no longer any significant
difference between treatment groups (for body or WAT
weights) due to the equol injections in the Phyto-low
group near the end of the experiment.
The Phyto-600 animals in experiment 2 (Phyto-low or
P h y t o - 6 0 0d i e te x p o s u r eb yt r e a t m e n tg r o u pf r o mc o n -
ception to 145 days of age) and in experiment 3 [Phyto-
200 diet exposure from conception to 45 days post-birth
at the supplier (ovariectomized). Upon arrival (45 days
of age) all animals were changed to the Phyto-low, then
one-half of the animals where changed to a Phyto-600
diet at 85 days of age until 100 days old] had lower
average body weights than the Phyto-low fed animals
but these differences were not significant. The animals
in experiment 2 were culled (due to the relatively large
numbers of animals initially) to remove any outliers
prior to treatment and had the shortest treatment peri-
ods (see methods). We believe that had treatment con-
tinued the Phyto-600 animals would have displayed
significantly lower body weights due to the observed
change in slopes of the body weights.
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(p < 0.001); however when normalized to body weight
(WAT/BW) this was not significant (p < 0.086). Equol
injections in the Phyto-low animals decreased body weight
a ss h o w ni nF i g u r e2 ,3 ,a n d5 .H o w e v e r ,o n l yi ne x p e r i -
ment 4 [Phyto-low or Phyto-600 diet exposure from con-
ception to approximately 100 day old when all animals
were ovariectomized. Then the animals remained on their
respective diet treatments (Phyto-low or Phyto-600) until
222 days of age)] were equol injections administered long
enough (approximately two weeks) to significantly demon-
strate this weight-reducing influence.
Porsolt forced swim test Experiments 1-4 demonstrated
no significant differences between treatment groups for
any behavioral study parameters in any of the PFSTs
performed in these experiments (Figure 1).
Serum isoflavone levels In experiments 1-3 serum levels
of daidzein, genistein, and equol were all significantly
lower in the Phyto-low animals (p < 0.001-0.008). Serum
equol levels of the equol-injected Phyto-low animals
were less than half the levels of the intestinally produced
equol in the Phyto-600 fed animals (Table 2). In experi-
ment 4, genistein and daidzein levels were significantly
less in the Phyto-low females (p < 0.005 and p < 0.006
respectively) while equol levels were significantly greater
(p < 0.002). In each of these experiments equol was the
major circulating phytoes t r o g e ni nb o t ht r e a t m e n t
groups while genistein and daidzein represented lower
percentages of the total phytoestrogen content.
Serum serotonin levels There were no significant differ-
ences in serum serotonin values between treatment
groups for experiments 1-4 (Phyto-low values ranged
between 262.9 + 107.3 to 544.9 + 205.9 vs Phyto-600
values ranged between 317.2 + 129.6 to 444.5 + 168.0).
These values were obtained at the end of each experi-
ment; prior serotonin values were not determined (data
not shown graphically).
Experiment 5: Phyto-low or Phyto-600 diet exposure from
conception to until the end of the experiment at 365 days of
age. All females experienced NOF at around 295 days old
Body weight and WAT Animal body weight measure-
ments were only recorded at specific points during this
Figure 2 Intact Diet-Changed Female Body Weight Changes. Experiment 1: (Phyto-low diet exposure from conception to 120 days post-birth
with diet change of one-half of the animals to a Phyto-600 diet until 210 days of age). Yellow diamond indicates diet treatment start and finish
dates; blue line indicates time body weights significantly different between treatment groups.
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marked in Figure 1. At the first PFST, which occurred
approximately a month after NOF, the Phyto-600 fed
animals had significantly lower body weights than the
Phyto-low animals (p < 0.05; Table 1). One week prior
to the second PFST, the Phyto-low animals received
daily equol injections. At the second PFST, animal body
weights were no longer significantly different between
treatment groups. However, WAT deposition was still
significantly greater in the Phyto-low fed animals (p <
0.05) and this trend continued even when WAT was nor-
malized to body weight WAT/BW (p < 0.05; Table 1).
Porsolt forced swim test In the first PFST, time immo-
bile (Figure 6), swimming distance (data not shown),
and overall average speed (data not shown) were signifi-
cantly higher in the Phyto-600 fed animals compared to
the Phyto-low fed animals (p < 0.005). This is the only
experiment where a dramatic and significant difference
between lifelong exposure to the diet treatments
occurred. Equol injection was also the most effective in
this experiment. For example, following the equol injec-
tions, immobility significantly decreased in the Phyto-
low fed animals compared to pre-equol injection values
(p < 0.05; Figure 6).
Figure 3 Intact Lifelong Diet Female Body Weight Changes.
Experiment 2: (Phyto-low or Phyto-600 diet exposure by treatment
group from conception to 145 days of age). No significant
differences were observed in body weights between the treatments
but values tended to be lower in the Phyto-600 vs. Phyto-low
animals and body weights in the Phyto-low fed animals declined
with equol injections (black line with end diamonds).
Figure 4 Ovariectomized Diet-Changed Female Body Weight Changes. Experiment 3: [Phyto-200 diet exposure from conception to 45 days
post-birth at the supplier (ovariectomized). Upon arrival (45 days of age) all animals were changed to the Phyto-low, then one-half of the
animals where changed to a Phyto-600 diet at 85 days of age until 100 days old]. No significant differences were observed in body weights
between the treatments but values tended to be lower in the Phyto-600 vs. Phyto-low animals.
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in Table 2. Serum levels of daidzein, genistein, and
equol (daidzein’s intestinal metabolite) were all signifi-
cantly lower in the Phyto-low animals compared to the
Phyto-600 animals prior to the first PFST (p < 0.001).
Following the second PFST only serum levels of
daidzein and genistein were significantly lower in the
Phyto-low animals compared to the Phyto-600 animals
(p < 0.001). Serum equol values were not significantly
different between treatment groups following the second
Figure 5 Ovariectomized Lifelong Diet Female Body Weight Changes. Experiment 4: Blue line indicates time body weights significantly different
between treatment groups. (Phyto-low or Phyto-600 diet exposure from conception to approximately 100 day old when all animals were
ovariectomized. Then the animals remained on their respective diet treatments (Phyto-low or Phyto-600) until 222 days of age). Equol injections (black
line with end diamonds)
Table 1 Body Weight Prior to Each Porsolt Test and Tissue Collection Body Weight, WAT and WAT/BW (grams,
MEAN ± SEM)
Experiment Diet 1
st PFST 2
nd PFST 3
rd PFST T.C. BW T.C. WAT WAT/BW
1 Phyto-low 330.4 ± 5.9 354.0 ± 5.7** 375.6 ± 7.3** 369.9 ± 80.4** 20.1 ± 1.7* 0.054 ± 0.004*
Phyto-600 327.6 ± 5.1 326.4 ± 5.4 332.6 ± 6.7 331.3 ± 6.4 13.1 ± 1.2 0.039 ± 0.003
2 Phyto-low 318.5 ± 15.0 338.2 ± 16.5 N/A 335.1 ± 15.8 16.1 ± 2.4 0.047 ± 0.005
Phyto-600 301.1 ± 12.9 323.2 ± 16.3 322.3 ± 15.2 11.9 ± 2.5 0.036 ± 0.006
3 Phyto-low 336.0 ± 7.3 N/A N/A 336.0 ± 7.3 16.0 ± 0.9 0.042 ± 0.005
Phyto-600 319.1 ± 6.8 N/A N/A 319.1 ± 6.8 11.4 ± 0.7# 0.032 ± 0.004
4 Phyto-low 431.0 ± 12.6* 487.1 ± 20.6* 454.4 ± 56.6 453.5 ± 19.3 23.4 ± 5.1 0.049 ± 0.009
Phyto-600 371.5 ± 15.4 414.6 ± 12.3 417.0 ± 57.8 413.6 ± 20.2 20.2 ± 2.0 0.048 ± 0.010
5 Phyto-low 526.5 ± 25.9* 507.9 ± 21.2 N/A 505.6 ± 21.0 32.1 ± 3.9# 0.063 ± 0.006#
Phyto-600 469.1 ± 21.3 472.1 ± 19.6 N/A 471.7 ± 19.0 23.3 ± 2.7 0.049 ± 0.005
Comparing diet and/or equol treatments within a column category: ** p < 0.001; * p < 0.01; # p < 0.05; PFST = Porsolt forced swim test, N/A = not assayed, T.C.
= tissue collection; BW = body weight; WAT = white adipose tissue deposition, Bold values = time of equol injection.
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total isoflavone concentrations.
Serum serotonin levels The Phyto-low fed animals dis-
played lower serum serotonin values prior to the first
PFST vs. Phyto-600 values (Figure 7). However, statistical
significance could not be numerically obtained between
treatment groups due to the low number of animals
whose blood was drawn prior to equol injections (n = 3
Phyto-low and n = 4 Phyto-600). We believe these find-
ings are noteworthy because the Phyto-600 values were
Table 2 Serum Levels of Isoflavones, Genistein and Daidzein, and Isoflavonoid Equol (all values in ng/ml ± 1.0)
Experiment Diet Genistein Daidzein Equol Total (G+D+E)
1 Phyto-low 8.1 ± 0.6* 4.8 ± 0.7* 439.1 ± 80.5* 452.0 ± 80.4*
Phyto-600 45.3 ± 8.4 34.9 ± 6.7 932.3 ± 121.4 1012.5 ± 135.5
2 Phyto-low 7.1 ± 1.4* 7.0 ± 0.8* 345.5 ± 97.1* 359.5 ± 96.5*
Phyto-600 32.1 ± 11.8 30.5 ± 5.1 753.5 ± 76.6 816.1 ± 81.0
3 Phyto-low 5.3 ± 1.1* 3.1 ± 0.3* 4.1 ± 0.4* 12.4 ± 1.4*
Phyto-600 48.5 ± 8.6 38.2 ± 7.0 495.6 ± 33.3 582.3 ± 31.2
4 Phyto-low 8.3 ± 0.4* 8.0 ± 1.7* 779.2 ± 60.4 # 792.2 ± 63.7 #
Phyto-600 36.0 ± 7.8 40.4 ± 9.2 415.1 ± 64.9 491.5 ± 76.3
5 Phyto-low
Before 4.6 ± 0.8* 3.1 ± 0.3* 4.0 ± 0.4* 11.1 ± 1.2*
After 3.7 ± 0.5* 3.1 ± 0.3* 376.3 ± 92.9 383.3 ± 92.0
Phyto-600
Before 31.4 ± 6.3 36.1 ± 7.1 339.7 ± 13.7 407.3 ± 27.0
After 25.2 ± 5.0 34.2 ± 6.5 321.6 ± 10.0 381.0 ± 21.0
* Phyto-low value significantly lower than Phyto-600 value; # Phyto-low value significantly higher than Phyto-600
value; ** Phyto-low Before value significantly lower than After value; Before refers to serum measured prior to 1
st
Porsolt test; After refers to serum measured after 2
nd Porsolt test.
Figure 6 Natural Ovarian Failure Female Time Immobile. Experiment 5: (Phyto-low or Phyto-600 diet exposure from conception to until the
end of the experiment at 365 days of age. All females experienced NOF at around 295 days old).Down yellow triangle Phyto-600 time immobile
significantly lower than Phyto-low animals. Down orange triangle Phyto-low After time immobile significantly decreased compared to Before
time immobile. Before refers to 1
st Porsolt test, After refers to 2
nd Porsolt test, all data expressed as the mean ± the standard error of the mean
(SEM).
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Page 9 of 13over 100 ng/ml greater (or 1.7 times higher) than the
Phyto-low values. Furthermore, following equol injec-
tions, the Phyto-low serotonin values significantly
increased compared to pre-injection levels (p < 0.042)
and were comparable to Phyto-600 values (Figure 7).
Discussion
In general, this study demonstrates that either dietary
isoflavone exposure or equol alone effectively decreased
body weight and WAT deposition in females regardless
of ovarian status, which is similar to that reported pre-
viously [17-20,24]. Of note, the primary isoflavone pre-
sent in the serum of rats fed a soy-rich diet is equol
(Table 2) while genistein and daidzein represent smaller
percentages of the total isoflavone count [18,19]. When
equol is injected alone, experiments 1, 4, and 5 demon-
strate that body weight still decreased. Equol has body
weight controlling effects in female rats is dependent on
age and initiation of the diet treatments. Neurobeha-
vioral influences may underlie the present effects due to
ovarian status and the dosage of isoflavonoids adminis-
tered [25]. However, while equol’s mechanism of action
is unknown, evidence to support the role of ERb’sa n t i -
adiposity in animals and humans has been reported
[26,27]. Moreover, animals fed soy-containing diets or
administered genistein appears to alter food intake and
metabolic hormones, body weight and adipose tissue
deposition as well as lipid uptake into adipocytes by
decreasing lipoprotein lipase (LPL) activity [18,19,28-32].
Daidzein also appears to decrease LPL activity, increase
lipolysis, and inhibit adipogenesis via estrogenic path-
ways [28,33,34]. Furthermore,u n p u b l i s h e dd a t ab yo u r
lab demonstrates that equol’s actions can be blocked by
an ER antagonist. Tamoxifen, a SERM able to antago-
nize ERs [35] is able to block the positive influence of
equol in human monolayer fibroblasts.
This study also demonstrated that equol decreases
depressive-related behavior in NOF females. Prior to
equol injections in experiment 5, the Phyto-low animals
demonstrated greater immobility and lower serotonin
levels. These differences were reversed following equol
injection as time immobile significantly decreased and
serum serotonin levels significantly increased in the
Phyto-low animals. This study is the first to test and
report equol’s potential effectiveness as an antidepres-
sant using the PFST. The testing of other isoflavones
such as quercitin or resveratrol in the PFST, while few
in number, demonstrate that isoflavones have potential
as antidepressant treatments [36,37].
Equol’s antidepressant potential demonstrated in the
PFST, may be attributed to equol’s estrogenic actions in
the brain. ERb is found in four brain regions associated
Figure 7 Natural Ovarian Failure Female Serum Serotonin Levels. Experiment 5: Down yellow triangle serotonin Before levels significantly
lower than After levels. Before refers to serum drawn prior to 1
st Porsolt test, After refers to serum analyzed after 2
nd Porsolt test, all values
expressed in ng/ml ± 1.0.
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Page 10 of 13with behavioral and mood disorders, the frontal cortex,
amygdala, hippocampus, and the hypothalamic region
[38-41]. Following dietary isoflavone exposure equol
levels in the frontal cortex are highest followed by
hypothalamus, amygdala, and the hippocampus [42],
demonstrating an ability for equol to concentrate in
these regions. Additionally, though the equol levels in
the amygdala, hypothalamus, and hippocampus are
lower, equol is still the primary isoflavone found in
these regions, representing over 80 to 90% of the total
isoflavone content of these brain areas [42].
Remarkably, equol could potentially affect the concen-
tration of serotonin. For example, Dewar et al., reported
that equol was an effective inhibitor of rat liver monoa-
mine oxidase [43]. Since monoamine oxidase is responsi-
ble for the deamination of monoamines, including
serotonin, this may account for the increase levels of this
important neurotransmitter associated with the positive
shift in depressive-like behaviors observed in the present
study. Notably, this was shown in NOF females fed a soy-
rich diet or equol administration alone in NOF females
fed a low-soy diet. Specifically, the raphe nucles of the
brain, which produces serotonin expresses ERb [44].
Lower serotonin levels are associated with depression in
humans [45-48]. Furthermore, the relationship between
serum and CSF serotonin levels indicates potential for
decreased serum serotonin concentrations to signify
depression [45]. Equol’sa b i l i t yt ob i n dE R b’si nv a r i o u s
brain regions may have increased serotonin levels and
improved mobility intervals in the PFST suggesting
equol’s potential as an antidepressant agent that repre-
sents quite novel results.
It is noteworthy that ERb-deficient mice express
increased anxiety [49] while administration of specific
ERb modulators in animal studies decrease anxiety and
depression [40,41,50,51]. Furthermore, in human studies
of depressed subjects, fluoxetine treatment increased
serum serotonin levels by 1.7-fold [52], a value similar
to that seen in experiment 5 in this study which may
suggest a similar mechanism of action or potentially an
increase in serotonin with enhanced catecholamine
levels as reported by others in human studies [53]. In
any event, further study for the potential of equol’s anti-
depressant actions is warranted.
However, the use of animals with varying ovarian sta-
tus demonstrated that equol appears to have a defined
range of effectiveness. For instance, ovarian status plays
a role in equol treatment effectiveness. Equol is ineffec-
tive at decreasing depressive-related behavior in intact
females or females ovariectomized shortly after puberty.
Experiments 1-4 all displayed no significant differences
in depressive-related behavior as measured by the PFST.
Only experiment 5 showed any significant differences.
Conversely, from this study it appears that equol has
potential as an anti-obesity treatment regardless of ovar-
ian status; however, as an antidepressant it appears to
be effective only following NOF.
Menopause/ovarian failure is a normal part of the aging
process [54]. Depression and obesity are associated with
menopause and affect both health and quality of life
[3,55]. Central obesity increases risk for many menopau-
sal conditions such as cardiovascular disease or breast
cancer [56,57]. Depression can cause menopausal symp-
toms and associated conditions to feel and appear more
s e r i o u s[ 5 5 ] .A d d i t i o n a l l y ,m o r ew o m e na r ee n t e r i n g
menopause prematurely due to either bilateral oophor-
ectomy or cancer treatment [2,55,58,59]. Severity of
menopausal symptoms and the risk of certain diseases
and conditions increase as age of menopause decreases
[60]. Furthermore, the five experiments in this study indi-
cate that timing and manner of ovarian failure can affect
treatment response. However, the extrapolation from ani-
mals to humans is not known.
Conclusions
The current study demonstrates that equol and/or isofla-
vonoids can decrease body weight, abdominal WAT, and
depressive-related behavior dependent on age at initia-
tion of diet and changes in ovarian status. However,
equol’s effectiveness as an antidepressant may be depen-
dent upon the changes/timing of ovarian status with
aging. This study demo n s t r a t e dt h a te q u o l ’s beneficial
effects are most clearly seen in female rats that have
undergone NOF. Further studies determining equol’s
exact mechanisms of action and potential as an antide-
pressant are required.
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